Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics:

• Overview of the current JAK inhibitor landscape (0:00)
• Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02)
• Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17)
• Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13)
• Available clinical data with novel BET inhibitors (15:00)
• Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50)
• Emerging efficacy and safety findings reported with imetelstat for MF (18:57)
• Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15)
• Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05)
• Other novel agents and strategies under investigation for MF (26:06)

CME information and select publications